Lercanidipin-Hcl Al

Lercanidipine hydrochloride, the active ingredient in Lercanidipin-Hcl Al, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension, helping to reduce the risk of cardiovascular complications. It is indicated for patients who require consistent blood pressure control and is part of standard antihypertensive therapy regimens.

GNH USA supplies Lercanidipin-Hcl Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Lercanidipine hydrochloride is used in the management of hypertension, a condition characterized by elevated arterial pressure. - Hypertension: lowers systolic and diastolic blood pressure, helping to control essential hypertension. - Isolated systolic hypertension: provides effective blood pressure reduction in elderly patients with isolated systolic elevation. - Secondary hypertension (adjunct therapy): may be added to other antihypertensives to achieve target blood pressure in resistant cases.

Lercanidipine hydrochloride may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Headache: mild to moderate headache reported. - Flushing: transient facial flushing. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness: sensation of lightheadedness, especially after standing.

Serious or Rare Side Effects: - Myocardial infarction: rare occurrence of heart attack. - Severe hypotension: marked drop in blood pressure causing fainting. - Allergic reactions: rash, pruritus, or angioedema.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Concomitant antihypertensives: adjust doses when used with other vasodilators to prevent additive effects. - Liver impairment: use cautiously in patients with hepatic dysfunction, as metabolism may be affected. - Elderly patients: start at low dose due to increased sensitivity to vasodilatory effects. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, raising risk of hypotension. - Grapefruit juice: can elevate drug concentration, leading to enhanced vasodilatory effects.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure lowering. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, decreasing effectiveness. - Beta‑blockers: combined use may affect heart rate control.